A Sanofi supported symposium at EAHAD 2023
Wednesday, February 8, 2023, 11:30-12:45 GMT
Exchange Auditorium, Manchester Central Convention Complex
Manchester, England
Event Information
Join us to learn about the emerging nonfactor therapies, including rebalancing agents, for managing hemophilia.
Hemophilia is incurable, but is manageable, most commonly through factor replacement prophylaxis with purified or recombinant clotting factor concentrates. Although factor replacement may be standard of care, this therapy is still associated with a high health burden and doesn’t always fit patient needs. Nonfactor therapies are in late-stage trials, which utilize multiple mechanisms of action, including treatments designed to inhibit natural anticoagulants to “rebalance” the hemostatic process. Given the rapid evolution of the non-replacement therapies for the management of hemophilia, it is important that clinicians be fully conversant with this emerging group of medications.
11:15 Doors open and lunch provided
11:30 Welcome and Introduction
11:35 The Balancing Act: What Do We Know?
11:50 Tipping the Scales: The Role of Rebalancing Agents in Achieving Hemostasis
12:10 Finding the Balance: Implications for the Present and Future
12:35 Summary of Key Points and Q and A
12:45 Adjourn